Steris

STE

Market cap $22.1B

STE rides on strong Healthcare and AST growth, but FX swings, tariffs, and rising costs cloud the outlook for investors.

Fast Retailing was a top contributor during the quarter, driven by strong execution across its global operations. Alibaba was a detractor during the quarter after the company reported mixed fiscal Q2 results. New positions were established in Sea Limited and Grab Holdings, while the portfolio's position in Atlassian was liquidated.

Steris (STE) reported earnings 30 days ago. What's next for the stock?

Explore Steris' (STE) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

STERIS offers a resilient, high-quality business model with some premium valuation, benefiting from hard-to-replicate sterilization networks and stable healthcare procedure volumes. Recent quarterly results included on-target 8% organic revenue growth but margin pressure from tariffs, with management raising tariff impact guidance by $10 million. STE stands to gain from stricter ethylene oxide (EtO) regulations, as compliance costs favor large, established players and will drive more outsourcing to its facilities.

STERIS plc (STE) Q3 2026 Earnings Call Transcript

STERIS shares slide after hours as Q3 earnings meet estimates and revenues beat, with investors focused on gross margin contraction despite solid growth.

The headline numbers for Steris (STE) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Steris (STE) came out with quarterly earnings of $2.53 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $2.32 per share a year ago.

Total revenue from continuing operations increased 9%; constant currency organic revenue grew 8% As reported EPS from continuing operations increased to $1.96; adjusted EPS increased to $2.53 Fiscal 2026 outlook maintained DUBLIN, IRELAND, Feb. 04, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2026 third quarter ended December 31, 2025. Total revenue from continuing operations for the third quarter of fiscal 2026 increased 9% to $1.5 billion compared with $1.4 billion in the third quarter of fiscal 2025.